Revising our attitudes towards agonist medications and their diversion in a time of pandemic.
J Subst Abuse Treat
; 119: 108139, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: covidwho-808920
ABSTRACT
The COVID-19 pandemic led government regulators to relax prescribing rules for buprenorphine and methadone, the agonist medications that effectively treat opioid use disorder, allowing for take home supplies of up to 28 days. These changes prioritized the availability of these medications over concerns about their misuse and diversion, and they provided a means for overdose prophylaxis during the highly uncertain conditions of the pandemic. In considering how to capitalize on this shift, research should determine the extent to which increased diversion has occurred as a result, and what the consequences may have been. The shifts also set the stage to consider if methadone can be safely prescribed in primary care settings, and if the monthly injectable formulation of buprenorphine is a suitable alternative to increased supplies of sublingual strips if concerns about diversion persist. The disruptions of the pandemic have caused a surge in overdose deaths, so carefully considering the prophylactic potential of agonist medications, in addition to their role as a treatment, may help us address this mortality crisis.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Pautas de la Práctica en Medicina
/
Infecciones por Coronavirus
/
Pandemias
/
Desvío de Medicamentos bajo Prescripción
/
Analgésicos Opioides
/
Trastornos Relacionados con Opioides
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Inglés
Revista:
J Subst Abuse Treat
Asunto de la revista:
Trastornos Relacionados con Sustancias
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS